netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.12  Expand sub section  Lipid-regulating drugs
Alirocumab (Praluent)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Restriction: In line with NICE Guidance only

 
Link  NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
Evolocumab (Repatha)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Restriction: In line with NICE Guidance only

 
Link  NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
02.12  Expand sub section  Bile acid sequestrants
Colestyramine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Colestyramine 4gram oral powder sachets

 
   
02.12  Expand sub section  Ezetimibe
Ezetimibe (Ezetrol)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Ezetimibe Tablet 10mg

Combined preparation with simvastatin (Inegy®) non-formulary

Use in accordance with locally agreed hyperlipidaemia guidelines

In line with NICE Guidance

 
Link  NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
   
02.12  Expand sub section  Fibrates
Bezafibrate 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Bezafibrate 200mg Tablet
Bezafibrate 400mg MR Tablet

Fibrates should not be offered routinely for the primary or secondary prevention of cardiovascular disease alone or in combination with a statin, including for those with chronic kidney disease or Type 1 or 2 Diabetes Mellitus. This does not apply to those diagnosed with familial hypercholesterolaemia (NICE CG181). 

 

 
Link  MHRA update: Fibrates not recommended as first-line treatment
   
02.12  Expand sub section  Statins to top
Atorvastatin 
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green

Atorvastatin 10mg Tablet
Atorvastatin 20mg Tablet
Atorvastatin 40mg Tablet
Atorvastatin 80mg Tablet

1st line agent. Use in accordance with locally agreed hyperlipidaemia guidelines

 
Simvastatin 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Simvastatin 10mg tablet
Simvastatin 20mg tablet
Simvastatin 40mg tablet 
Simvastatin 80mg tablet

Use in accordance with locally agreed hyperlipidaemia guidelines

 
   
02.12  Expand sub section  Nicotinic acid group
Acipimox (Olbetam)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Acipimox 250mg capsules

 
   
02.12  Expand sub section  Omega-3 fatty acid compounds
Omacor 
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Grey

Not approved for inclusion in the North Staffordshire Joint Formulary 

 
NHS England Guidance for CCGs:

 prescribers in primary care should not initiate omega-3 Fatty Acids for any new patient.
 prescribers should be supported in deprescribing omega-3 Fatty Acids in all patients and, where appropriate, ensure the availability of relevant services to facilitate this change.

 
Link  NICE CG172: Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary